Articles from Linnaeus Therapeutics

Linnaeus Therapeutics Announces Selection of LNS8801 into the National Institute on Aging Interventions Testing Program

Selection by both the NIA ITP and ARPA-H PROSPR programs highlights growing recognition of LNS8801’s potential to promote healthy aging

By Linnaeus Therapeutics · Via GlobeNewswire · June 9, 2026

Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance LNS8801 for Healthspan Preservation

ARPA-H PROSPR program to support accelerated development of LNS8801 to promote healthy aging

By Linnaeus Therapeutics · Via GlobeNewswire · February 24, 2026

Articles from Linnaeus Therapeutics | WAOW